(ACRV) Acrivon Therapeutics - Ratings and Ratios
ACR-368, ACR-2316, Companion Diagnostics, AP3 Platform
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 81.1% |
| Value at Risk 5%th | 113% |
| Relative Tail Risk | -15.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.25 |
| Alpha | -91.50 |
| CAGR/Max DD | -0.44 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.379 |
| Beta | 1.745 |
| Beta Downside | 2.337 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.47% |
| Mean DD | 69.07% |
| Median DD | 72.78% |
Description: ACRV Acrivon Therapeutics December 22, 2025
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is a clinical-stage biopharma focused on oncology, leveraging its generative phosphoproteomics platform (AP3) to develop drug-specific companion diagnostics (OncoSignature) that match patients to targeted therapies. Its lead candidate, ACR-368, is a selective CHK1/CHK2 inhibitor aimed at endometrial and platinum-resistant ovarian cancers as well as squamous cell carcinomas (e.g., SCCHN, anal cancer). Additional programs include ACR-2316, a dual WEE1/PKMYT1 inhibitor, and a preclinical cell-cycle pipeline built on AP3 and co-crystallography.
As of the latest public filing (Q3 2024), ACRV reported approximately $45 million in cash and marketable securities, giving it roughly 12-month runway at its reported quarterly burn of $15 million. The company raised $50 million in a June 2024 private placement, diluting existing shareholders but extending its cash runway into 2025. Its market capitalization hovers around $150 million, placing it in the lower-mid tier of U.S. biotech peers.
Key sector drivers that could influence ACRV’s valuation include the overall growth of the oncology drug market (projected ~8% CAGR through 2028), increasing payer acceptance of biomarker-driven therapies, and the competitive landscape for CHK1/2 inhibitors, where several larger firms are pursuing similar mechanisms. A successful Phase 2 readout for ACR-368 would be a material catalyst, but the company remains vulnerable to trial delays, regulatory setbacks, and the need for additional financing.
For a deeper, data-focused look at ACRV’s risk-adjusted upside, you might find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-81.8m TTM) > 0 and > 6% of Revenue (6% = 50.9k TTM) |
| FCFTA -0.47 (>2.0%) and ΔFCFTA -17.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.6k% (prev 9244 %; Δ 4372 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.45 (>3.0%) and CFO -65.8m > Net Income -81.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (38.6m) change vs 12m ago 1.19% (target <= -2.0% for YES) |
| Gross Margin -43.16% (prev 53.66%; Δ -96.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.47% (prev 0.88%; Δ -0.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -19.66
| (A) 0.79 = (Total Current Assets 130.4m - Total Current Liabilities 14.9m) / Total Assets 145.3m |
| (B) -1.76 = Retained Earnings (Balance) -255.9m / Total Assets 145.3m |
| warn (B) unusual magnitude: -1.76 — check mapping/units |
| (C) -0.45 = EBIT TTM -81.8m / Avg Total Assets 180.0m |
| (D) -15.32 = Book Value of Equity -255.8m / Total Liabilities 16.7m |
| Total Rating: -19.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 43.15
| 1. Piotroski 0.0pt |
| 2. FCF Yield 139.9% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda 0.40 |
| 6. ROIC - WACC (= -54.41)% |
| 7. RoE -53.71% |
| 8. Rev. Trend 15.09% |
| 9. EPS Trend 42.77% |
What is the price of ACRV shares?
Over the past week, the price has changed by -2.97%, over one month by -3.38%, over three months by +19.90% and over the past year by -66.27%.
Is ACRV a buy, sell or hold?
- Strong Buy: 4
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACRV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.2 | 387.8% |
| Analysts Target Price | 11.2 | 387.8% |
| ValueRay Target Price | 2 | -11.4% |
ACRV Fundamental Data Overview January 04, 2026
P/B = 0.5913
Beta = 1.77
Revenue TTM = 848.0k USD
EBIT TTM = -81.8m USD
EBITDA TTM = -80.5m USD
Long Term Debt = 2.99m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.18m USD (from shortTermDebt, last quarter)
Debt = 2.99m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -32.4m USD (from netDebt column, last quarter)
Enterprise Value = -48.6m USD (77.6m + Debt 2.99m - CCE 129.3m)
Interest Coverage Ratio = unknown (Ebit TTM -81.8m / Interest Expense TTM 0.0)
FCF Yield = 139.9% (FCF TTM -68.1m / Enterprise Value -48.6m)
FCF Margin = -8027 % (FCF TTM -68.1m / Revenue TTM 848.0k)
Net Margin = -9640 % (Net Income TTM -81.8m / Revenue TTM 848.0k)
Gross Margin = -43.16% ((Revenue TTM 848.0k - Cost of Revenue TTM 1.21m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = -0.33 (set to none) (Enterprise Value -48.6m / Total Assets 145.3m)
Interest Expense / Debt = 54.77% (Interest Expense 1.64m / Debt 2.99m)
Taxrate = 21.0% (US default 21%)
NOPAT = -64.6m (EBIT -81.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.75 (Total Current Assets 130.4m / Total Current Liabilities 14.9m)
Debt / Equity = 0.02 (Debt 2.99m / totalStockholderEquity, last quarter 128.6m)
Debt / EBITDA = 0.40 (negative EBITDA) (Net Debt -32.4m / EBITDA -80.5m)
Debt / FCF = 0.48 (negative FCF - burning cash) (Net Debt -32.4m / FCF TTM -68.1m)
Total Stockholder Equity = 152.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -56.26% (Net Income -81.8m / Total Assets 145.3m)
RoE = -53.71% (Net Income TTM -81.8m / Total Stockholder Equity 152.2m)
RoCE = -52.68% (EBIT -81.8m / Capital Employed (Equity 152.2m + L.T.Debt 2.99m))
RoIC = -42.43% (negative operating profit) (NOPAT -64.6m / Invested Capital 152.2m)
WACC = 11.98% (E(77.6m)/V(80.6m) * Re(12.44%) + (debt cost/tax rate unavailable))
Discount Rate = 12.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 191.5%
Fair Price DCF = unknown (Cash Flow -68.1m)
EPS Correlation: 42.77 | EPS CAGR: 3.16% | SUE: 3.09 | # QB: 4
Revenue Correlation: 15.09 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.49 | Chg30d=+0.172 | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=-1.91 | Chg30d=+0.374 | Revisions Net=+1 | Growth EPS=+3.1% | Growth Revenue=+802.4%
Additional Sources for ACRV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle